問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD7984C00002
Active

2023-07-01 - 2030-02-28

Phase III

Not yet recruiting1

Recruiting10

ICD-10C53.9

Malignant neoplasm of cervix uteri, unspecified

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9180.9

Malignant neoplasm of cervix uteri, unspecified

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/07/01

Investigators and Locations

Principal Investigator Yu-Fang Huang

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chien-Hsing Lu

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Peng-Hui Wang

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator 劉文雄

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 張志隆

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 蕭聖謀

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 吳貞璇

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Lian-Shung Yeh Division of Obstetrics & Gynecology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 陳子和 Division of Obstetrics & Gynecology

Co-Principal Investigator

  • 林子棋 Division of Obstetrics & Gynecology
  • 賴冠銘 Division of Hematology & Oncology
  • 曾若涵 Division of Hematology & Oncology
  • 林炫聿 Division of Hematology & Oncology
  • 簡宏如 Division of Obstetrics & Gynecology

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    36 participants

  • Global

    800 participants